Novavax presents data on developing seasonal influenza nanoparticles for RSV

US-based, clinical-stage vaccine company Novavax has presented data for the company’s nanoparticle programme at the New Approaches to Vaccines for Human and Veterinary Tropical Diseases Keystone Symposia in Cape Town, South Africa.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news